IL276300B2 - Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer - Google Patents
Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancerInfo
- Publication number
- IL276300B2 IL276300B2 IL276300A IL27630020A IL276300B2 IL 276300 B2 IL276300 B2 IL 276300B2 IL 276300 A IL276300 A IL 276300A IL 27630020 A IL27630020 A IL 27630020A IL 276300 B2 IL276300 B2 IL 276300B2
- Authority
- IL
- Israel
- Prior art keywords
- xaa
- grpr
- antagonist
- cooh
- ala
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705513P | 2012-09-25 | 2012-09-25 | |
| PCT/US2013/061712 WO2014052471A1 (en) | 2012-09-25 | 2013-09-25 | Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL276300A IL276300A (en) | 2020-09-30 |
| IL276300B1 IL276300B1 (en) | 2024-06-01 |
| IL276300B2 true IL276300B2 (en) | 2024-10-01 |
Family
ID=49887190
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL276300A IL276300B2 (en) | 2012-09-25 | 2013-09-25 | Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer |
| IL312551A IL312551B2 (en) | 2012-09-25 | 2013-09-25 | GRPR antagonists for detection, diagnosis and treatment of GRPR-positive cancer |
| IL237844A IL237844B (en) | 2012-09-25 | 2015-03-19 | Radiolabeled grpr antagonists for diagnostic imaging and treatment of grpr-positive cancer |
| IL256649A IL256649B (en) | 2012-09-25 | 2017-12-28 | Grpr antagonists for the detection, diagnosis and treatment of grpr-positive cancer |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312551A IL312551B2 (en) | 2012-09-25 | 2013-09-25 | GRPR antagonists for detection, diagnosis and treatment of GRPR-positive cancer |
| IL237844A IL237844B (en) | 2012-09-25 | 2015-03-19 | Radiolabeled grpr antagonists for diagnostic imaging and treatment of grpr-positive cancer |
| IL256649A IL256649B (en) | 2012-09-25 | 2017-12-28 | Grpr antagonists for the detection, diagnosis and treatment of grpr-positive cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (7) | US9839703B2 (https=) |
| EP (2) | EP2900279B1 (https=) |
| JP (4) | JP6562838B2 (https=) |
| KR (2) | KR102190005B1 (https=) |
| AU (4) | AU2013323596C1 (https=) |
| BR (1) | BR112015006453B1 (https=) |
| CA (2) | CA3114832A1 (https=) |
| DK (1) | DK2900279T3 (https=) |
| ES (1) | ES2745635T3 (https=) |
| HR (1) | HRP20191620T1 (https=) |
| HU (1) | HUE045724T2 (https=) |
| IL (4) | IL276300B2 (https=) |
| LT (1) | LT2900279T (https=) |
| MX (1) | MX362675B (https=) |
| PL (1) | PL2900279T3 (https=) |
| PT (1) | PT2900279T (https=) |
| RU (1) | RU2693465C9 (https=) |
| SI (1) | SI2900279T1 (https=) |
| WO (1) | WO2014052471A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2841238C (en) * | 2011-07-08 | 2019-10-01 | Biosynthema Inc. | Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
| ES2745635T3 (es) | 2012-09-25 | 2020-03-03 | Advanced Accelerator Applications Usa Inc | Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR |
| EP3015462A1 (en) * | 2014-10-29 | 2016-05-04 | OctreoPharm Schiences GmbH | Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals |
| EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
| US11857352B2 (en) | 2016-09-06 | 2024-01-02 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
| ES2814555T3 (es) | 2016-11-28 | 2021-03-29 | Bayer Pharma AG | Compuestos de quelato de gadolinio con alta relaxividad para usar en la obtención de imágenes por resonancia magnética |
| HRP20231458T1 (hr) | 2017-01-12 | 2024-05-10 | Radiomedix Inc. | Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima |
| CA3112060A1 (en) * | 2018-10-12 | 2020-04-16 | Advanced Accelerator Applications International Sa | Pharmaceutical composition comprising a radiolabeled gprp antagonist and a surfactant |
| WO2021068051A1 (en) * | 2018-11-13 | 2021-04-15 | Provincial Health Services Authority | Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders |
| KR102934987B1 (ko) | 2018-11-23 | 2026-03-09 | 바이엘 악티엔게젤샤프트 | 조영 매체의 제형 및 그의 제조 방법 |
| KR20220063218A (ko) * | 2019-09-16 | 2022-05-17 | 노파르티스 아게 | 안정한 농축 방사성 약제학적 조성물 |
| TWI878344B (zh) * | 2019-09-17 | 2025-04-01 | 瑞士商諾華公司 | 放射性標記grpr拮抗劑之方法及其套組 |
| JP2022549258A (ja) * | 2019-09-24 | 2022-11-24 | ノバルティス アーゲー | セラノスティックスとして使用するための放射性標識ｇｒｐｒアンタゴニスト |
| CA3153267A1 (en) * | 2019-12-19 | 2021-06-24 | Hans-Jurgen Wester | Modified grpr antagonist peptides for imaging and therapy of cancer |
| AU2023239751A1 (en) | 2022-03-25 | 2024-09-05 | Provincial Health Services Authority | Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders |
| WO2026083422A1 (en) * | 2024-10-20 | 2026-04-23 | Starget Pharma Ltd | Cyclic grpr binding peptides |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019647A (en) * | 1988-05-24 | 1991-05-28 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4943561A (en) * | 1988-11-28 | 1990-07-24 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
| US5028692A (en) | 1989-04-25 | 1991-07-02 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
| IE903958A1 (en) | 1989-11-06 | 1991-05-08 | Erba Carlo Spa | Reduced irreversible bombesin antagonists |
| WO1993016105A1 (en) | 1992-02-07 | 1993-08-19 | Merrell Dow Pharmaceuticals Inc. | Phenylalanine analogs of bombesin |
| US5620955A (en) * | 1993-06-18 | 1997-04-15 | Peptide Technologies Corporation | Bombesin receptor antagonists and uses thereof |
| EP1033372A4 (en) | 1997-11-18 | 2000-10-04 | Chugai Pharmaceutical Co Ltd | COMPOSITIONS WITH ANTI-TUMOR ACTIVITY |
| JP5139678B2 (ja) | 2003-07-24 | 2013-02-06 | ブラッコ・イメージング・ソシエタ・ペル・アチオニ | 安定な放射性医薬品組成物およびその製法 |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| IN2013MN01188A (https=) | 2010-11-22 | 2015-07-10 | Piramal Imaging Sa | |
| CA2841238C (en) * | 2011-07-08 | 2019-10-01 | Biosynthema Inc. | Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
| ES2745635T3 (es) * | 2012-09-25 | 2020-03-03 | Advanced Accelerator Applications Usa Inc | Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR |
-
2013
- 2013-09-25 ES ES13815181T patent/ES2745635T3/es active Active
- 2013-09-25 HR HRP20191620 patent/HRP20191620T1/hr unknown
- 2013-09-25 BR BR112015006453-1A patent/BR112015006453B1/pt active IP Right Grant
- 2013-09-25 SI SI201331585T patent/SI2900279T1/sl unknown
- 2013-09-25 JP JP2015534625A patent/JP6562838B2/ja active Active
- 2013-09-25 AU AU2013323596A patent/AU2013323596C1/en active Active
- 2013-09-25 EP EP13815181.6A patent/EP2900279B1/en active Active
- 2013-09-25 IL IL276300A patent/IL276300B2/en unknown
- 2013-09-25 KR KR1020157007572A patent/KR102190005B1/ko active Active
- 2013-09-25 CA CA3114832A patent/CA3114832A1/en active Pending
- 2013-09-25 LT LT13815181T patent/LT2900279T/lt unknown
- 2013-09-25 US US14/431,096 patent/US9839703B2/en active Active
- 2013-09-25 KR KR1020207034970A patent/KR102314293B1/ko active Active
- 2013-09-25 IL IL312551A patent/IL312551B2/en unknown
- 2013-09-25 WO PCT/US2013/061712 patent/WO2014052471A1/en not_active Ceased
- 2013-09-25 DK DK13815181.6T patent/DK2900279T3/da active
- 2013-09-25 CA CA2886068A patent/CA2886068C/en active Active
- 2013-09-25 HU HUE13815181A patent/HUE045724T2/hu unknown
- 2013-09-25 RU RU2015115529A patent/RU2693465C9/ru active
- 2013-09-25 EP EP19170067.3A patent/EP3536347A1/en active Pending
- 2013-09-25 PL PL13815181T patent/PL2900279T3/pl unknown
- 2013-09-25 MX MX2015003772A patent/MX362675B/es active IP Right Grant
- 2013-09-25 PT PT138151816T patent/PT2900279T/pt unknown
-
2015
- 2015-03-19 IL IL237844A patent/IL237844B/en active IP Right Review Request
-
2017
- 2017-11-20 US US15/817,776 patent/US20180133349A1/en not_active Abandoned
- 2017-12-28 IL IL256649A patent/IL256649B/en active IP Right Grant
-
2018
- 2018-06-21 AU AU2018204513A patent/AU2018204513C1/en active Active
-
2019
- 2019-06-04 JP JP2019104379A patent/JP6997135B2/ja active Active
- 2019-08-16 AU AU2019216714A patent/AU2019216714B2/en active Active
- 2019-09-24 US US16/580,990 patent/US11083805B2/en active Active
-
2021
- 2021-03-26 AU AU2021201914A patent/AU2021201914B2/en active Active
- 2021-07-23 US US17/383,577 patent/US12064491B2/en active Active
- 2021-07-23 US US17/383,550 patent/US12064489B2/en active Active
- 2021-07-23 US US17/383,567 patent/US12064490B2/en active Active
- 2021-09-22 JP JP2021154188A patent/JP7358430B2/ja active Active
-
2023
- 2023-07-13 JP JP2023115231A patent/JP7534498B2/ja active Active
-
2024
- 2024-07-15 US US18/773,055 patent/US20240366812A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019647A (en) * | 1988-05-24 | 1991-05-28 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
Non-Patent Citations (2)
| Title |
|---|
| ABD-ELGALIEL W R ET AL,, DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF AN ANTAGONIST-BOMBESIN ANALOGUE AS TARGETING VECTO, 23 September 2008 (2008-09-23) * |
| DAVID C. HEIMBROOK ET AL,, GASTRIN RELEASING PEPTIDE ANTAGONISTS WITH IMPROVED POTENCY AND STABILITY, 1 July 1991 (1991-07-01) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276300B2 (en) | Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer | |
| AU2009221204B2 (en) | Bombesin analog peptide antagonist conjugates | |
| AU2019469641B2 (en) | Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders | |
| Cantorias et al. | MO tripeptide diastereomers (M= 99/99mTc, Re): models to identify the structure of 99mTc peptide targeted radiopharmaceuticals | |
| Makris et al. | Synthesis and evaluation of fac-[99mTc/Re (CO) 3]+ complexes with a new (N, S, N) bifunctional chelating agent: The first example of a fac-[Re (CO) 3 (N, S, N-sst2-ANT)] complex bearing a somatostatin receptor antagonist peptide | |
| WO2026083422A1 (en) | Cyclic grpr binding peptides |